An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/2/2019 |
| Start Date: | March 13, 2018 |
| End Date: | April 16, 2022 |
| Contact: | Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, |
| Email: | Clinical.Trials@bms.com |
| Phone: | please email: |
ADaptiVe Biomarker Trial That InformS Evolution of Therapy
The purpose of this study is to evaluate the treatment of solid tumors with various
immunotherapy combinations. The treatment will be determined based upon a broad biomarker
assessment.
immunotherapy combinations. The treatment will be determined based upon a broad biomarker
assessment.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com
Inclusion Criteria:
- Participants must have an ECOG performance status of less than or equal to 1
- Participants must have had prior therapy
- Participants must have at least 2 lesions with measurable disease as defined by RECIST
Version 1.1
Exclusion Criteria:
- Participants must not have suspected, known, or progressive CNS metastases, have
untreated CNS metastases, or have the CNS as the only site of disease
- Participants must not have carcinomatous meningitis
- Participants must not have other active malignancy requiring concurrent intervention
Other protocol defined inclusion/exclusion criteria could apply
We found this trial at
3
sites
University of Chicago One of the world's premier academic and research institutions, the University of...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials